The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
Open accessAbstract
Purpose: To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS). Patients and Methods: We compared the long-term outcome of patients with MDS treated with EPO plus G-CSF (n = 121) with untreated patients (n = 237) with MDS using multivariate Cox regression with delayed entry, for the first time adjusting for all major prognostic variables (WHO classification, karyotype, cytopenias, level of transfusion-need, age, and sex). Results: The erythroid response rate to EPO plus G-CSF was 39%, and the median response duration 23 months (range, 3 to 116+). In the multivariate analysis, treatment was associated with improved overall survival (hazard ratio, 0.61; 95% CI, 0.44 to 0.83; P = .002). Interestingly, this positive association was primarily observed in patients requiring fewer than 2 units of RBCs per month. Treatment was not linked to the rate of acute myeloid leukemia in any defined subgroup, including patients with an increase of marrow blasts or an unfavorable karyotype. Conclusion: The inherent risk of leukemic evolution in MDS makes the current investigation highly relevant, in light of the recent reports of potential negative effects of EPO treatment on outcome in patients with cancer. We conclude that treatment of anemia in MDS with EPO plus G-CSF may have a positive impact on outcome in patients with no or low transfusion need, while not affecting the risk of leukemic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
- Statistical Models for Epidemiology
(2013) · Bayesian Methods in Epidemiology · doi:10.1201/b15382-9 · Cited by 1,346
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,032
Self-citationBlood Transfusion in Elderly Patients with Acute Myocardial Infarction
Wu, W.-C., Rathore, S. S., Wang, Y., Radford, M. J., & Krumholz, H. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010615 · Cited by 952
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Self-citationLeyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
Corwin, H. L., Gettinger, A., Fabian, T. C., May, A., Pearl, R. G., Heard, S., An, R., Bowers, P. J., Burton, P., Klausner, M. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071533 · Cited by 545
Hellström‐Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M. S., Dybedal, I., Grimfors, G., Hesse‐Sundin, E., Hjorth, M., Kanter‐Lewensohn, L., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04153.x · Cited by 458
Self-citationRituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., et al. (2006) · Blood · doi:10.1182/blood-2006-01-0233 · Cited by 452
Rosenberg, P. S. (2006) · Blood · doi:10.1182/blood-2005-11-4370 · Cited by 431
Wright, J. R., Ung, Y. C., Julian, J. A., Pritchard, K. I., Whelan, T. J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1514 · Cited by 428
Heaney, M. L., & Golde, D. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402107 · Cited by 388
Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 343
Self-citationAnemia and decline in physical performance among older persons
Penninx, B. W. J. H., Guralnik, J. M., Onder, G., Ferrucci, L., Wallace, R. B., & Pahor, M. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00263-8 · Cited by 341
Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.-T., et al. (2008) · Blood · doi:10.1182/blood-2007-06-096370 · Cited by 334
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3396 · Cited by 327
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
Self-citationGuidelines for the diagnosis and therapy of adult myelodysplastic syndromes
Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., Parker, J., & of the UK MDS Guidelines Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03907.x · Cited by 298
Pellagatti, A., Jädersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610477104 · Cited by 233
Self-citationLong-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jädersten, M., Montgomery, S. M., Dybedal, I., Porwit-MacDonald, A., & Hellström-Lindberg, E. (2005) · Blood · doi:10.1182/blood-2004-10-3872 · Cited by 205
Self-citationErythropoietin induces tumor regression and antitumor immune responses in murine myeloma models
Mittelman, M., Neumann, D., Peled, A., Kanter, P., & Haran-Ghera, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081275298 · Cited by 158
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegović, B., Goode, M. J., Jakubowski, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-08-109488 · Cited by 151
The WHO classification of MDS does make a difference
Howe, R. B., Porwit‐MacDonald, A., Wanat, R., Tehranchi, R., & Hellström-Lindberg, E. (2003) · Blood · doi:10.1182/blood-2003-06-2124 · Cited by 147
Self-citationQuality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes
Jansen, A. J. G., Essink‐Bot, M., Beckers, E. A. M., Hop, W. C. J., Schipperus, M. R., & van Rhenen, D. J. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04272.x · Cited by 144
Conditions for Bias from Differential Left Truncation
Howards, P. P., Hertz‐Picciotto, I., & Poole, C. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwk027 · Cited by 121
Socié, G., Mary, J., Schrezenmeier, H., Marsh, J. C. W., Bacigalupo, A. P., Locasciulli, A., Führer, M., Békássy, A. N., Tichelli, A., & Passweg, J. R. (2006) · Blood · doi:10.1182/blood-2006-07-034272 · Cited by 119
Sloand, E. M., Yong, A. S. M., Ramkissoon, S. H., Solomou, E. E., Bruno, T. C., Kim, S., Führer, M., Kajigaya, S., Barrett, A. J., & Young, N. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605245103 · Cited by 116
Spiriti, M. A. A., Latagliata, R., Niscola, P., Cortelezzi, A., Francesconi, M., Ferrari, D., Volpe, E., Clavio, M., Grossi, A., Reyes, M. T., et al. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0961-9 · Cited by 107
Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P. D., Loeffler, M., Diehl, V., & Tesch, H. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02016.x · Cited by 101
Expression and function of erythropoietin receptors in tumors
Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., & Begley, C. G. (2007) · Cancer · doi:10.1002/cncr.22832 · Cited by 99
Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer
Khuri, F. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078101 · Cited by 99
Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E., & Amadori, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi400 · Cited by 96
Balleari, E., Rossi, E., Clavio, M., Congiu, A. M., Gobbi, M., Grosso, M., Secondo, V., Spriano, M., Timitilli, S., & Ghio, R. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0044-6 · Cited by 88
Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome
Olíva, E. N., Dimitrov, B. D., Benedetto, F. A., D’Angelo, A., & Nobile, F. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.03.004 · Cited by 84
Erythropoietin, the FDA, and Oncology
Steinbrook, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078100 · Cited by 62
Tehranchi, R., Fadeel, B., Schmidt‐Mende, J., Forsblom, A., Emanuelsson, E. K., Jädersten, M., Christensson, B., Hast, R., Howe, R. B., Samuelsson, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1850 · Cited by 38
Self-citationTemkin, S. M., Hellmann, M., Serur, E., et al. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00709.x · Cited by 32
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Self-citationAdès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Erythropoietin or darbepoetin for patients with cancer
Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub5 · Cited by 392
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Self-citation
Metadata
- Authors
- Jädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-20
- Volume
- 26
- Issue
- 21
- Pages
- 3607-3613
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165036959
- Cited by
- 300
- References
- 42
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.